GEN0101

Norio Nonomura · Phase 1 active Small molecule Quality 0/100

GEN0101 is an investigational drug developed by Norio Nonomura, currently in early clinical trials for advanced melanoma and recurrent castration-resistant prostate cancer (CRPC). The drug is being evaluated in combination with pembrolizumab and as a monotherapy. No FDA label is available, and the drug's safety and efficacy are still under investigation.

At a glance

Generic name	GEN0101
Sponsor	Norio Nonomura
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GEN0101 CI brief — competitive landscape report
GEN0101 updates RSS · CI watch RSS
Norio Nonomura portfolio CI